ArticleParasites & vectors2025
The ability of an oral combination of afoxolaner, moxidectin and pyrantel to protect dogs from Borrelia burgdorferi infections transmitted by Ixodes scapularis.
Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Comparative speed of kill of induced Ixodes scapularis infestations following treatment of dogs with endectocides containing either sarolaner (Simparica Trio™), afoxolaner (NexGardParasites & vectors · 2026Article
- Efficacy of Credelio Quattro™ chewable tablets containing lotilaner, moxidectin, pyrantel, and praziquantel against Ctenocephalides felis and Rhipicephalus sanguineus infestations on dogs.Parasites & vectors · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTwo studies were conducted to determine whether treatment with NexGard
methodsFor each study, 20 dogs were randomly assigned to two groups (n = 10/group): NP and negative control. Twenty-eight days post-treatment, each dog was infested with approximately 50 I. scapularis that had a 60% B. burgdorferi infection rate in study 1 and a 38.5% infection rate in study 2. Five days post-infestation, ticks were counted and removed. The B. burgdorferi-specific C6 antibody was tested for using the SNAP
resultsOn the day of count and removal, no ticks were found on treated dogs, while control dogs had an average of 25.1 ticks in study 1 and 19.6 ticks in study 2, for efficacy of 100% (P ≤ 0.0001). All dogs were seronegative before infestation. The first dog in the control groups became seropositive 21 days post-infestation in study 1 and 35 days post-infestation in study 2 by the SNAP 4Dx test and by 21 days post-infestation by the Lyme Quant C6 test in both studies. Ten of 10 dogs in the control group in both studies seroconverted by the end of the study. None of the skin biopsies from treated dogs were positive for B. burgdorferi DNA, while at least three of the four skin biopsies from each of the control dogs tested positive at the end of the studies. No clinical signs of Lyme disease were detected in any of the dogs.
conclusionsThe results of these studies indicate that NexGard
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.